IPM Take
A targeted therapy is not precision care simply because it targets a gene.
For children with KCNT1-related developmental and epileptic encephalopathy, the science is entering the clinic. But the real test starts outside the laboratory: can families obtain a timely diagnosis, reach specialist care, navigate referral and travel, and access a trial before delay becomes another part of the disease?
The molecule may be targeted. The system still is not.
Executive Summary
Servier announced that the first US patient has been enrolled in its Phase Ib/II first-in-human study of S230815, an investigational antisense oligonucleotide for children with KCNT1-related developmental and epileptic encephalopathy, or KCNT1-DEE.
The study is designed to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects. S230815 is administered intrathecally and is designed to degrade KCNT1 messenger RNA, with the aim of reducing the disease-driving activity associated with pathogenic KCNT1 variants. There are no human efficacy findings yet.
The study is recruiting, with sites open in the United States, Europe and Japan. The Servier trial page lists an estimated enrolment of 20 participants across 11 locations, with additional US centres planned. (PR Newswire)
Why it matters
- Patients / advocates: First-patient enrolment is a meaningful milestone. It is not treatment access. Families still need diagnosis, specialist referral and the practical ability to reach a trial centre.
- Clinicians: Genetic confirmation cannot remain a slow administrative endpoint. In rare developmental epilepsies, it increasingly determines prognosis, eligibility and the possibility of entering a targeted study.
- Researchers / academia: Rare-disease trials cannot rely on scientific readiness alone. They need referral networks, natural-history evidence and study designs built around families rather than sponsor convenience.
For a child with a rare genetic epilepsy, the hardest part is often not discovering that a trial exists.
It is getting close enough to it.
KCNT1-related developmental and epileptic encephalopathy can begin in the first days or months of life. It can bring severe seizures, profound developmental impairment and a relentless cycle of medication changes, emergency care and uncertainty. There are currently no curative or disease-modifying treatments.
Servier’s study creates a first clinical route for a therapy designed to act on the genetic pathway itself. That is the promise of precision medicine at its most direct: identify the biological driver, build a treatment around it and test whether changing that driver can alter the disease.
But a trial does not automatically create a pathway.
A clinician has to suspect a genetic epilepsy. Testing has to be ordered and interpreted. A family has to reach an expert centre. A referral has to be completed. The study site has to be reachable across borders, languages, insurance systems and exhausted family lives.
Every break in that chain becomes an access decision, even when nobody calls it one.
The study is at the starting line. It must first show that S230815 can be delivered safely and that the biology moves in the intended direction. But its launch already exposes the wider challenge: when precision therapies emerge for very small patient populations, can health systems find the children who need them in time?
